Vita Therapeutics is a biotechnology company generating state-of-the-art cellular therapeutics for the treatment of debilitating neuromuscular diseases and cancers. It uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics has completed Series A financing of $32 million and is currently working with numerous partners, including PanCella, Wyss Institute, and Johns Hopkins University, to advance clinical programs.